Picture of Beximco Pharmaceuticals logo

BXP — Beximco Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Beximco Pharma. - Q1 Financial Results 2026-27


		
		
		
		
		
		
	
	
RNS Number : 0079D
Beximco Pharmaceuticals PLC
13 November 2026
 

13 November 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Financial Results for the First Quarter Ended 30 September 2026

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three-month period ended 30 September 2026. The financial statements have been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.

Beximco Pharma Managing Director, S. M. Rabbur Reza, commented:

“We are pleased to share today’s results which demonstrate the underlying strength and resilience of Beximco Pharma’s business. Despite the ongoing macro-economic challenges, we have continued to deliver revenue and profitability growth into the new financial year, and we look forward to building on this progress for shareholders and patients as we continue to execute on our strategy and provide high-quality and affordable medicines to patients in Bangladesh and around the world.”

 

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

 

For further information please visit www.beximcopharma.com or enquire to:

 

Beximco Pharma

S. M. Rabbur Reza, Managing Director

Tel: +880 2 58611001, Ext. 20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

 

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting 

Ben Atwell / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals PLC.

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

 

Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

 

 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at 30 September 2026

 

 

30 September 2026

 

Taka ‘000

 

30 June 2026

ASSETS

 

 

 

 

 

 

 

Property, plant and equipment

45,768,049

 

45,602,684

Right-of-use assets

344,443

 

359,773

Intangible assets

4,462,167

 

4,551,852

Deferred tax asset

16,695

 

19,651

Goodwill

674,570

 

674,570

Investment in associates

15,365

 

15,365

Other investments

5,430

 

6,733

Total non-current assets

51,286,719

 

51,230,628

 

 

 

 

Inventories

14,586,089

 

13,988,599

Spares and supplies

969,145

 

1,010,233

Trade and other receivables

3,189,015

 

3,669,562

Loans, advances, deposits and prepayments

3,108,316

 

3,220,130

Advance income tax

415,097

 

402,402

Short term investment

1,500,000

 

950,000

Cash and cash equivalents

8,466,259

 

6,668,012

Total current assets

32,233,921

 

29,908,938

TOTAL ASSETS

83,520,640

 

81,139,566

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

Share capital

4,461,121

 

4,461,121

Share premium

5,269,475

 

5,269,475

Excess of issue price over face value of GDRs

1,689,637

 

1,689,637

Capital reserve on merger

294,951

 

294,951

Revaluation surplus

1,130,144

 

1,130,821

Unrealized gain/(loss)

2,604

 

3,908

Retained earnings

51,795,427

 

49,241,292

Total shareholders' equity

64,643,359

 

62,091,205

Non-controlling interest

4,146,833

 

4,103,149

 

 

 

 

TOTAL EQUITY

68,790,192

 

66,194,354

 

 

 

 

Long term borrowings-net of current maturity

1,462,374

 

1,738,988

Liability for gratuity and WPPF

3,788,877

 

3,395,314

Deferred tax liability

2,796,303

 

2,758,010

Non-current liabilities

8,047,554

 

7,892,312

 

 

 

 

Short term borrowings

1,909,140

 

2,303,467

Long term borrowings-current maturity

574,942

 

586,629

Trade and other payables

1,865,496

 

1,952,971

Accrued expenses

1,189,545

 

1,422,556

Dividend payable

122,629

 

137,954

Income tax payable

1,021,142

 

649,323

Total current liabilities

6,682,894

 

7,052,900

Total liabilities

14,730,448

 

14,945,212

TOTAL EQUITY AND LIABILITIES

83,520,640

 

81,139,566

 

 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July 2026-September 2026

 

 

 

 

 

Taka ‘000

 

 

 

 

 

 

 

 

July 2026–September 2026

 

July 2025–September 2025

 

 

 

 

 

Net revenue

 

14,657,933

 

13,794,829

Cost of goods sold

 

(7,482,950)

 

(7,132,749)

Gross profit

 

7,174,983

 

6,662,080

 

 

 

 

 

General and administrative expenses

 

(384,332)

 

(354,695)

Selling, marketing and distribution expenses

 

(3,392,187)

 

(3,013,639)

Operating expenses

      

         (3,776,519)

 

(3,368,334)

Profit from operations

 

3,398,464

 

3,293,746

 

 

 

 

 

Other income

 

304,844

 

169,395

Finance cost

 

(105,885)

 

(186,310)

Profit before tax and WPPF

 

3,597,423

 

3,276,831

Contribution to WPPF

 

(172,466)

 

(157,156)

 

 

 

 

 

Profit before tax

 

3,424,957

 

3,119,675

Current tax

 

(786,566)

 

(702,569)

Deferred tax

 

(41,446)

 

(15,845)

Income tax expenses

 

(828,012)

 

(718,414)

Profit after tax

 

2,596,945

 

2,401,261

 

 

 

 

 

Owners of the Company

 

2,553,261

 

2,363,099

Non-controlling interest

 

43,684

 

38,162

Profit/(loss) attributable

 

2,596,945

 

2,401,261

Other comprehensive income/(loss)

 

(1,304)

 

-

Total comprehensive income

 

2,595,641

 

2,401,261

 

 

 

 

 

Owners of the Company

 

2,551,957

 

2,363,099

Non-controlling interest

 

43,684

 

38,162

Total comprehensive income attributable

 

2,595,641

 

2,401,261

 

 

 

 

 

Earnings per share (EPS)

 

5.72

 

5.30

 

 

 

 

 

 

 


Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July 2026-September 2026

 

 

For the period July 2026-September 2026

Taka ‘000

 

 

 

Share capital

 

Share premium

 

Excess of issue price over face value of GDRs

 

Capital reserve on merger

 

Revaluation surplus

 

Unrealized gain/(loss)

 

Retained earnings

Equity attributable to owners of the Company

 

Non-controlling interest

 

Total

Balance as on 01 July 2026

4,461,121

5,269,475

1,689,637

294,951

1,130,821

3,908

49,241,292

62,091,205

4,103,149

66,194,354

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income:

 

Profit for the period

-

-

-

-

-

-

2,553,261

2,553,261

43,684

2,596,945

Other comprehensive income/(loss)

-

-

-

-

-

(1,304)

-

(1,304)

-

(1,304)

Transactions with the shareholders:

 

Cash dividend

-

-

-

-

-

-

                     -

                     -

                            -

                           -

Others:

 

Adjustment for depreciation on revalued assets

-

-

-

-

(874)

-

874

-

                             -

-

Adjustment for deferred tax on revalued assets

-

-

-

-

197

-

-

197

-

197

Balance as on 30 September 2026

4,461,121

5,269,475

1,689,637

294,951

1,130,144

2,604

51,795,427

64,643,359

4,146,833

68,790,192

Net assets value (NAV) per share                                                                                                                                                                                  Tk.                  144.90             

 

For the period July 2025-September 2025

 

 

Share capital

 

Share premium

 

Excess of issue price over face value of GDRs

 

Capital reserve on merger

 

Revaluation surplus

 

Unrealized gain/(loss)

 

Retained earnings

Equity attributable to owners of the Company

 

Non-controlling interest

 

Total

Balance as on 01 July 2025

4,461,121

5,269,475

1,689,637

294,951

1,133,870

18,149

40,239,934

53,107,137

3,977,499

57,084,636

Total comprehensive income:

 

 

 

 

 

 

 

 

 

 

Profit for the period

-

-

-

-

-

-

2,363,099

2,363,099

38,162

2,401,261

Other comprehensive income/(loss)

-

-

-

-

-

-

-

-

-

-

Transactions with the shareholders:

Cash dividend

-

 

 

 

 

 

-

-

-

-

Others:

Adjustment for depreciation on revalued assets

-

-

-

-

(984)

-

984

-

-

-

Adjustment for deferred tax on revalued assets

-

-

-

-

221

-

-

221

-

221

Balance as on 30 September 2025

4,461,121

5,269,475

1,689,637

294,951

1,133,107

18,149

42,604,017

55,470,457

4,015,661

59,486,118

Net assets value (NAV) per share                                                                                                                                                                                   Tk.                  124.34                      

 


 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July 2026-September 2026

 

 

July 2026– September 2026

 

Taka ‘000

 

July 2025– September 2025

Cash flows from operating activities:

 

 

 

 

 

 

 

Cash receipts from customers and others

15,258,385

 

13,822,950

Cash paid to suppliers and employees

(11,276,123)

 

(10,498,856)

Cash generated from operations

3,982,262

 

3,324,094

 

 

 

 

Interest paid

(118,697)

 

(199,501)

Interest received

157,544

 

63,704

Income tax paid

(427,442)

 

(450,451)

Net cash generated from operating activities

3,593,667

 

2,737,846

 

 

 

 

Cash flows from investing activities:

 

 

 

Acquisition of property, plant and equipment

(576,511)

 

(984,442)

Intangible assets

(3,561)

 

(92,909)

Disposal of property, plant and equipment

14,018

 

-

Short term investment

(550,000)

 

(100,000)

Net cash used in investing activities

(1,116,054)

 

(1,177,351)

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Net increase/(decrease) in long term borrowings

(271,399)

 

(463,728)

Net increase/(decrease) in short term borrowings

(394,327)

 

7,978

Dividend paid

(15,325)

 

(163,858)

Net cash from/(used in) financing activities

(681,051)

 

(619,608)

Increase/(decrease) in cash and cash equivalents

1,796,562

 

940,887

Opening cash and cash equivalents

6,668,012

 

1,700,097

Effect of exchange rate changes on cash and cash equivalents

1,685

 

8,136

Closing cash and cash equivalents

  8,466,259

 

2,649,120

 

 

 

 

Net operating cash flows per share

8.06

 

6.14

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFFFFFMEEMSEIF

Recent news on Beximco Pharmaceuticals

See all news